Table 1 Patient Characteristics
Variable | Frequency (%) |
|---|---|
Age median [range], years | 57.6 [28.6–84.0] |
Gender | |
Male | 39 (77%) |
Female | 12 (23%) |
Significant history of tobacco use | |
Yes | 34 (67%) |
No | 17 (33%) |
Significant history of alcohol use | |
Yes | 13 (25%) |
No | 38 (75%) |
Primary Site | |
Oropharynx | 22 (43%) |
Unknown Primary | 7 (13%) |
Hypopharynx | 4 (8%) |
Skin | 4 (8%) |
Larynx | 4 (8%) |
Major Salivary Gland | 4 (8%) |
Sinonasal | 3 (6%) |
Nasopharynx | 2 (4%) |
Oral cavity | 1 (2%) |
Pathology | |
Squamous cell carcinoma | 47 (92%) |
Acinic cell carcinoma | 1 (2%) |
Adenoid cystic carcinoma | 1 (2%) |
Myoepithelial carcinoma | 1 (2%) |
Salivary duct carcinoma | 1 (2%) |
T stage | |
2 | 2 (4%) |
3 | 7 (14%) |
4A | 36 (70%) |
4B | 4 (8%) |
4C | 2 (4%) |
Prior neck dissection | |
Yes | 27 (53%) |
No | 24 (47%) |
Chemotherapy (initial treatment) | |
Yes | 36 (71%) |
No | 15 (29%) |
Median initial XRT dose [range], Gy | 66.0 [50–72] |
Type of salvage Neck Dissection | |
Modified Radical Neck Dissection | 36 (71%) |
Radical Neck Dissection | 15 (29%) |
Interstitial Brachytherapy | |
Median dose [range], Gy | 60 [40–62] |
Average dose ± std., Gy | 57.7 ± 4.8 |
Average duration [range], d | 5 [3–6] |
Average dose rate [range], cGy/h | 60 (36–90) |